Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2,4-Dichlorobenzyl alcohol is a mild antiseptic with broad-spectrum antibacterial and antiviral properties, primarily indicated for the treatment of mouth and throat infections such as acute pharyngitis. It functions by denaturing proteins and disrupting the lipid bilayers of pathogen cell membranes and viral envelopes. Historically developed by Boots and utilized in various formulations by companies like MEDICE Arzneimittel Puetter, it is most commonly found in over-the-counter lozenges. It is frequently combined with amylmetacresol to enhance its antimicrobial efficacy against a wide range of pathogens, including those associated with the common cold and sore throats.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,4-dichlorobenzyl alcohol.